CervoMed closes $10M registered direct offering at $4.00 per share

CervoMed Inc. completed a registered direct offering of 2.5 million shares at $4.00 per share, raising $10 million gross proceeds for working capital and general corporate purposes. The funding supports the clinical-stage biotech's development of neflamapimod for age-related brain disorders, with Phase 3 trials contingent on additional financing or partnerships.